Chester County News and Community Website
WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) has issued a series of important updates addressing healthcare challenges, regulatory actions, and emerging safety concerns, with implications for medical …
Health Alert: FDA Exposes Life-Threatening Risks, Device Shortages, and Food Safety Failures You Need to Know Now! Read More
KING OF PRUSSIA, PA — SEED Therapeutics Inc. has announced that its molecular glue therapy, ST-01156, has been granted Rare Pediatric Disease and Orphan Drug designations by the U.S. Food and …
SEED Therapeutics Secures FDA Rare Pediatric and Orphan Drug Designations for ST-01156 Read More
WEST CHESTER, PA — Molecular Targeting Technologies, Inc. (MTTI) has unveiled significant preclinical results for its proprietary Ac-EBTATE radiopharmaceutical, demonstrating remarkable efficacy against somatostatin receptor-2-positive neuroendocrine tumors (NETs), including small …
Promising New Radiopharmaceutical Shows Breakthrough Potential in Cancer Treatment Read More
WASHINGTON, D.C. — The Food and Drug Administration (FDA) recently granted accelerated approval to Epkinly (epcoritamab-bysp), a new treatment option for adults with relapsed or refractory follicular lymphoma (FL). This …
FDA Grants Accelerated Approval to New Treatment for Relapsed Follicular Lymphoma Read More
WASHINGTON, D.C. — The Food and Drug Administration (FDA) recently granted accelerated approval for a new treatment combination for adults with KRAS G12C-mutated locally advanced or metastatic colorectal cancer (CRC). …
FDA Grants Accelerated Approval to New Colorectal Cancer Treatment Read More
WASHINGTON, D.C. — The FDA on Wednesday granted full approval to the drug selpercatinib, marketed as Retevmo, for treating advanced thyroid cancer in both adults and children aged 2 and …
FDA Grants Full Approval to Retevmo for Advanced Thyroid Cancer Read More WASHINGTON, D.C. — In a significant advancement for patients with rare blood diseases, the U.S. Food and Drug Administration (FDA) has given its nod to Bkemv (eculizumab-aeeb), the first interchangeable …
FDA Approves Bkemv, A Potentially Game-Changing Treatment for Rare Blood Diseases Read More
HORSHAM, PA — In a significant medical breakthrough, Johnson & Johnson recently announced FDA’s approval of CARVYKTI® for the treatment of adult patients with multiple myeloma. This approval marks a …
FDA Approves Johnson & Johnson’s Innovative, Immuno-Targeted Multiple Myeloma Therapy, CARVYKTI Read More
NEWTOWN SQUARE, PA — In recent developments from the pharmaceutical industry, ArriVent BioPharma Inc. (Nasdaq: AVBP), a notable player in the arena of breakthrough cancer therapy, has seen a transformative …
ArriVent BioPharma Unveils Promising Developments and Strong Financial Performance in 2023 Read More
PLYMOUTH MEETING, PA — The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to Harmony Biosciences Holdings, Inc.’s (Nasdaq: HRMY) pitolisant for the treatment of Prader-Willi syndrome …
Harmony Biosciences Secures FDA Orphan Drug Designation for Pitolisant in Prader-Willi Syndrome Treatment Read More